|
Federal Partners in Bullying Prevention
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, HRSA, IHS, SAMHSA
|
NICHD, NIAAA, NIDA, OD/DPCPSI/OBSSR, NIMH
|
The mission of the Federal Partners in Bullying Prevention is to provide information from a broad array of government agencies on the identification and prevention of and ways to respond to bullying and cyberbullying, as well as individuals most at risk to experience it.
|
|
Federal RePORTER
|
Resource Development
|
ACF, ACL, AHRQ, CDC, FDA
|
OD/OER
|
Federal RePORTER is a searchable public database of scientific awards from federal agencies, which allows for portfolio analysis and metrics development across scientific domains. The trans-federal agency consortium called STAR METRICS (Science and Technology for America’s Reinvestment Measuring the Effects of Research on Innovation, Competitiveness, and Science) designed, created, and maintains Federal RePORTER.
|
|
Federal Sudden Unexpected Infant Death/Sudden Infant Death Syndrome (SUID/SIDS) Workgroup
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, HRSA, IHS
|
NICHD
|
The purpose of the partnership is to establish and enhance relationships among Federal agencies with responsibilities for SIDS and SUID. The partner agencies intend to work together to improve communication and coordination, and to collaborate on a range of activities designed to reduce, and, ultimately, eliminate SIDS and SUID, including the elimination of racial, ethnic and socio-economic disparities.
|
|
Federal Supply and Demand of Isotopes
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIBIB, NCI
|
A workshop on Isotope Federal Supply and Demand is held annually. The workgroup that organizes this workshop consists of representatives of federal agencies with the aim of providing a forum for interaction between agencies, departments, and medical societies to communicate about potential shortages of isotopes that are of strategic importance to the nation including the availability of medical isotopes. Also, a report of isotope supply and demand and whether needs are commercially available is compiled by the National Institutes of Health (NIH) and submitted to DOE annually. The report includes demand for NIH intramural research programs and NIH extramural projects (grantees). Not included in this report are NIH intramural research needs that are supplied by its cyclotron or isotope needs to be met by commercial suppliers. NIH collects data from ICs and submits annual reports as required. On January 12, 2021, DOE, NIH, and the members of the Isotope Needs Program held the 7th Workshop on Isotope Federal Supply and Demand. The meeting reviewed the Program’s ongoing activities and reported that the newly evolving use of electron- and alpha-emitting isotopes are seeing increased need (based on FDA’s approval for medical applications); the DOE is developing a plan to meet the current and foreseen increased use of these isotopes for cancer therapy. In support of these efforts, NIBIB conducted an August 16-17, 2021 workshop that focused on instrumentation development to directly image these new electron- and alpha-emitting isotopes for enhancing cancer therapy outcomes. https://www.imagingtherapy.nibib.nih.gov/
|
|
Federal Tuberculosis (TB) Task Force
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, OS
|
NICHD, NIAID
|
The Federal Tuberculosis (TB) Task Force is a coalition composed of the federal agencies involved in U.S. TB research and control efforts. Established in 1991, it facilitates coordination of activities among these federal agencies.
|
|
Federal Work Group on Suicide Prevention
|
Committee, Work group, Advisory group, or Task Force
|
SAMHSA, CDC, IHS, ACF, ACL, AHRQ, HRSA, ASPE
|
NIDA, NIMH, NIAAA
|
The Federal Work Group on Suicide Prevention, led by the Substance Abuse and Mental Health Services Administration (SAMHSA), brings together multiples agencies within HHS and across agencies (e.g., Veterans Affairs, Department of Transportation, Department of Justice) to meet and discuss suicide prevention initiatives within the federal government on a quarterly basis. Meeting topics range from SAMHSA updates on the 988 implementation and other initiatives to a round robin which provides a forum for federal agencies to share various suicide prevention initiatives they are leading or are involved in.
|
|
Federal Working Group on Bone Diseases
|
Committee, Work group, Advisory group, or Task Force
|
CDC, CMS, FDA
|
NIAMS, CSR, NCATS, NCI, NIA, NIAID, NICHD, NIDCR, NIDDK, OD/DPCPSI/ORWH, NIAAA
|
An interagency committee focusing on osteoporosis and other bone disorders. It offers a forum for sharing information, learning from each other and invited speakers, and facilitating the development, early in the planning stages, of collaborative research activities based on each agency's mission.
|
|
Filovirus Animal Non-Clinical Group (FANG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NIAID
|
The Filovirus Animal Non-Clinical Group (FANG) focuses on the advanced development of Filovirus medical countermeasures (MCM), both vaccines and therapeutics. The FANG focuses on the product development tools and other interagency product development issues relevant to FDA approval of filovirus MCM. A standing interagency working group, the Portfolio Advisory Committee, oversees the FANG. The FANG will develop strategies to address broadly applicable and interagency product development issues relevant to licensure of filovirus MCM. The FANG will develop consensus recommendations to facilitate standardization of reagents, methods, and procedures across multiple agencies and laboratories.
|
|
Filovirus Animal Non-Clinical Group (FANG) Workshop
|
Meeting/ Workshop
|
CDC, FDA, OS
|
NIAID
|
The Filovirus Animal Non-Clinical Group (FANG) focuses on the advanced development of Filovirus medical countermeasures (MCM), both vaccines and therapeutics. The primary focus of the Workshop will be on Marburg virus, although other filoviruses will also be addressed.
|
|
FNIH Advanced Medicines Partnership® - Bespoke Gene Therapy Consortium (FNIH AMP BGTC)
|
Research Initiative
|
FDA
|
NCATS
|
Working with the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), private sector partners, and FNIH to execute AAV gene therapy research, clinical and manufacturing workstreams.
|